Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 651 to 700 of 757

TitleReference numberPublishedLast updated
Pharmalgen for the treatment of bee and wasp venom allergyTA246
Tocilizumab for the treatment of rheumatoid arthritisTA247
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapyTA242
Rituximab for the first-line treatment of stage III-IV follicular lymphomaTA243
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adultsTA245
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancerTA118
Tocilizumab for the treatment of systemic juvenile idiopathic arthritisTA238
Fulvestrant for the treatment of locally advanced or metastatic breast cancerTA239
Ticagrelor for the treatment of acute coronary syndromesTA236
Mifamurtide for the treatment of osteosarcomaTA235
Bortezomib and thalidomide for the first‑line treatment of multiple myelomaTA228
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusionTA229
Agomelatine for the treatment of major depressive episodes (terminated appraisal)TA231
Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarctionTA73
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancerTA227
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugsTA225
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphomaTA226
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial diseaseTA223
Golimumab for the treatment of psoriatic arthritisTA220
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemiaTA218
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancerTA214
Bendamustine for the first-line treatment of chronic lymphocytic leukaemiaTA216
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 yearsTA213
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular eventsTA210
Prucalopride for the treatment of chronic constipation in womenTA211
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancerTA212
Trastuzumab for the treatment of HER2-positive metastatic gastric cancerTA208
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumoursTA209
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumoursTA86
Denosumab for the prevention of osteoporotic fractures in postmenopausal womenTA204
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)TA206
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)TA207
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis CTA200
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitorTA195
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritisTA199
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemiaTA193
Capecitabine for the treatment of advanced gastric cancerTA191
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancerTA192
Human growth hormone (somatropin) for the treatment of growth failure in childrenTA188
Infliximab and adalimumab for the treatment of Crohn's diseaseTA187
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromesTA47
Topotecan for the treatment of relapsed small-cell lung cancerTA184
Topotecan for the treatment of recurrent and stage IVB cervical cancerTA183
Guidance on the use of electroconvulsive therapyTA59
Sunitinib for the treatment of gastrointestinal stromal tumoursTA179
Pemetrexed for the first-line treatment of non-small-cell lung cancerTA181
Alitretinoin for the treatment of severe chronic hand eczemaTA177
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinomaTA178
Tenofovir disoproxil for the treatment of chronic hepatitis BTA173
Rituximab for the first-line treatment of chronic lymphocytic leukaemiaTA174

Results per page

  1. 10
  2. 25
  3. 50
  4. All